Email updates

Keep up to date with the latest news and content from BMC Bioinformatics and BioMed Central.

This article is part of the supplement: Selected Proceedings of the 2010 AMIA Summit on Translational Bioinformatics

Open Access Proceedings

An integrative method for scoring candidate genes from association studies: application to warfarin dosing

Nicholas P Tatonetti14, Joel T Dudley12, Hersh Sagreiya3, Atul J Butte2 and Russ B Altman4*

Author Affiliations

1 Biomedical Informatics Training Program, Stanford University School of Medicine, Stanford, CA, USA

2 Departments of Pediatrics and Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA

3 Stanford University School of Medicine, Stanford, CA, USA

4 Departments of Bioengineering and Genetics, Stanford, CA 94305-5479, USA

For all author emails, please log on.

BMC Bioinformatics 2010, 11(Suppl 9):S9  doi:10.1186/1471-2105-11-S9-S9

Published: 28 October 2010

Abstract

Background

A key challenge in pharmacogenomics is the identification of genes whose variants contribute to drug response phenotypes, which can include severe adverse effects. Pharmacogenomics GWAS attempt to elucidate genotypes predictive of drug response. However, the size of these studies has severely limited their power and potential application. We propose a novel knowledge integration and SNP aggregation approach for identifying genes impacting drug response. Our SNP aggregation method characterizes the degree to which uncommon alleles of a gene are associated with drug response. We first use pre-existing knowledge sources to rank pharmacogenes by their likelihood to affect drug response. We then define a summary score for each gene based on allele frequencies and train linear and logistic regression classifiers to predict drug response phenotypes.

Results

We applied our method to a published warfarin GWAS data set comprising 181 individuals. We find that our method can increase the power of the GWAS to identify both VKORC1 and CYP2C9 as warfarin pharmacogenes, where the original analysis had only identified VKORC1. Additionally, we find that our method can be used to discriminate between low-dose (AUROC=0.886) and high-dose (AUROC=0.764) responders.

Conclusions

Our method offers a new route for candidate pharmacogene discovery from pharmacogenomics GWAS, and serves as a foundation for future work in methods for predictive pharmacogenomics.